Towards a simple objective framework for the investigation and treatment of cancer cachexia: The Glasgow Prognostic Score

Douglas, E.; McMillan, Donald C.

doi:10.1016/j.ctrv.2013.11.007

Cited by 133 publications

(108 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, routine use of the mGPS may also direct future therapeutic strategies, targeted at the systemic inflammatory response itself. Indeed, it is now appreciated that systemic inflammation is complicit in cancer cachexia, 22 and may be attenuated by the use of non-steroidal anti-inflammatory drugs (NSAIDs). 23 A similar scheme may also be applied to patients undergoing potentially curative surgery.…”

Section: Discussionmentioning

confidence: 99%

Colorectal Cancer, Systemic Inflammation, and Outcome

et al. 2016

Self Cite

View full text Add to dashboard Cite

Running head: colorectal cancer and systemic inflammation 1 Mini-AbstractOf measures of the systemic inflammatory response, the modified Glasgow Prognostic Score has been most extensively validated in cancer. The present study examined its clinical utility in a large cohort of patients undergoing potentially curative resection of colorectal cancer. 2 Abstract ObjectiveThe present study aims to examine the clinical utility of the combination of TNM stage and modified Glasgow Prognostic Score (mGPS) in patients undergoing potentially curative resection of colorectal cancer (CRC). Background

show abstract

Section: Discussionmentioning

confidence: 99%

Colorectal Cancer, Systemic Inflammation, and Outcome

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies have established reduced serum albumin as a marker of poor prognosis in cancer patients [6,7,9,[13][14][15] and also of a patient's capacity to endure aggressive cancer therapy [16,17]. A reduced albumin level has previously been attributed to the consuming nature of the cancer [3,7].…”

Section: Discussionmentioning

confidence: 99%

“…However, cancer patients are a special population with an inherently high risk of VTE, warranting a detailed investigation of the association between albumin levels and VTE occurrence. A decrease in serum albumin in cancer patients has further been recognized as an expression of the consuming nature of the neoplasm and is associated with poor prognosis in cohorts of different malignancies [6][7][8][9]. It is currently not clear whether serum albumin is actively involved in mechanisms that lead to the occurrence of VTE and death or whether the observed association is a manifestation of underlying inflammatory processes [5], a renal loss of albumin in kidney disease [4], or an unknown process.…”

Section: Introductionmentioning

confidence: 99%

Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients

et al. 2016

View full text Add to dashboard Cite

Background. In cancer patients, reduced serum albumin has been described as a marker for global declining health and poor prognosis. Our aim was to investigate the association of albumin concentrations with the occurrence of venous thromboembolism (VTE) and mortality in patients with cancer. Methods. This investigation was performed in the framework of the Vienna Cancer and Thrombosis Study (CATS), a prospective observational cohort study. We included 1,070 patients with active cancer and assayed serum albumin from venous blood taken at study inclusion. Risk for occurrence of VTE was calculated in a proportional subdistribution hazard regression model with respect to competing risk of death and adjusted for cancer site, leukocyte count, estimated glomerular filtration rate, and cholinesterase.

show abstract

“…Eighty percent of patients were diagnosed with an oesophageal or junctional cancer, with metastatic disease evident in 40% of cases. Median CRP was 29mg/L (interquartile range 13-74), and median albumin was 31g/L (26)(27)(28)(29)(30)(31)(32)(33)(34)(35)). An elevated CRP (>10mg/L) was present in 78% of patients, and a low albumin (<35g/L) was identified in 75% of patients.…”

Section: Resultsmentioning

confidence: 99%

“…A targeted role for such agents in improving nutritional status as well as alleviating symptoms of cachexia has been proposed. [29][30][31] In keeping with this, a multi-modality approach incorporating non-steroidal anti-inflammatory drugs and nutritional support has been shown to be feasible in patients with advanced cancer. [32] The presently recruiting MENAC trial aims to investigate the effects of such an intervention on body composition and performance status in patients receiving palliative chemotherapy for advanced pancreatic and lung cancer.…”

Section: Discussionmentioning

confidence: 95%

Palliative stenting for oesophagogastric cancer: tumour and host factors and prognosis

Park

Woodley

Glen

2018

BMJ Support Palliat Care

View full text Add to dashboard Cite

ObjectivesPalliative self-expandable metallic stent (SEMS) insertion is common in patients not suitable for resection of oesophago-gastric (OG) cancer. Factors which may determine survival however are not clear. The present study examined the relationship between tumour and host factors, including the systemic inflammatory response, and survival of patients undergoing palliative SEMS insertion. MethodsPatients with a diagnosis of OG cancer who were considered suitable for palliative SEMS only without systemic therapy were identified. Patient characteristics including Eastern Cooperative Oncology Group performance status, radiological stage and modified Glasgow were associated with shorter survival. The combination of performance status and mGPS stratified three-month survival of patients without metastatic disease from 88% to 20% (P<0.001) and patients with metastases from 43% to 6% (P=0.059). Similar results were 3 observed when analysis was restricted to patients with oesophageal and junctional cancer (M0: 83% to 20%, P=0.008; M1: 33% to 8%, P=0.082). ConclusionPerformance status, metastatic disease and mGPS are independent predictors of survival in patients with OG cancer undergoing palliative SEMS insertion. These routinely available markers provide a rational system on which to base decisions regarding prognosis and treatment.

show abstract

Towards a simple objective framework for the investigation and treatment of cancer cachexia: The Glasgow Prognostic Score

Cited by 133 publications

References 66 publications

Colorectal Cancer, Systemic Inflammation, and Outcome

Colorectal Cancer, Systemic Inflammation, and Outcome

Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients

Palliative stenting for oesophagogastric cancer: tumour and host factors and prognosis

Contact Info

Product

Resources

About